RoboSense Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units
8.11.2022 15:28:00 EET | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, held a new product launch and Tech Day event. During the conference, RoboSense officially launched RS-LiDAR-E1 (E1), a flash solid-state LiDAR that sees 360° based on its in-house, custom developed chips and flash technology platform. Also debuted was the only China National Accreditation Service (CNAS) recognized on-board LiDAR lab of the industry to date, and held the unveiling ceremony of the smart manufacturing joint venture, Luxsense, jointly with Luxshare-ICT, a domestic leading electronics manufacturer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221108005666/en/
RoboSense Tech Day Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units (Graphic: Business Wire)
RoboSense launched E1, the first automotive-grade flash solid-state LiDAR. It serves as a new product platform featuring area array transceiver technology with application-specific developed chips as the core. E1 is designed for large-scale series production with a simple bill of materials including no moving parts, and excels in all the three aspects of detection performance, cost efficiency and automotive-grade safety and reliability of LiDARs. As a key piece to realizing the core functions of autonomous driving, E1 will assist partners to further bridge the gap in smart driving perception and improve the all-scenario perception capability of automated and autonomous vehicles.
4 core features of E1
- Horizontal FOV of 120°, which ensures 360° coverage area without blind zone using minimum sensors.
- Vertical FOV is designed to be 90°, to allow the perception area to cover both blind zones on the ground and lateral vision.
- Ultra-high frame rates of over 25Hz, capturing target objects’ motion states and predicting their moves faster.
- Detection range of 30m @10%, which enables better perception planning control.
E1 uses RoboSense’s first in-house, custom chips for flash solid-state LiDAR platform and its first 2D electronic scanning technology. With highly integrated chips that incorporate the three core components of transmission, reception, and processing, E1 greatly streamlines the circuit design and production processes, creating the performance and cost advantages necessary for the durability and reliability requirements of blind spot LiDARs in the automotive market.
To ensure product performance and rapidly improve production capacity, RoboSense launched the first and only CNAS certified LiDAR lab to analyze LiDAR and their components and developed a complementary smart manufacturing system to produce this high-tech, precision sensor.
During the event, leaders of RoboSense and Luxshare jointly held the unveiling ceremony of Luxsense. Investment in the first phase of RoboSense smart manufacturing system exceeded 1 billion RMB cumulatively; the plant area exceeds 55,000 square meters including nearly 20 automated production lines built with highly intelligent production software to achieve a top-level production efficiency of “a LiDAR every 12 seconds” and guarantees capacity by connecting our Shenzhen, Dongguan and Guangzhou plants.
Additionally, RoboSense announced a new strategic financing round which attracted top industry investors. In particular, industry investors in this new financing round include car companies with self-owned brands, emerging automakers, top luxury supercar brands, leading commercial vehicle companies, supply chain pioneers and the tier 1 institutions. Greatly empowered by capital investments from the industry, RoboSense gained unprecedented momentum and sustainability.
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005666/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom